Kitov Pharamceut Ads (KTOV) 3.25 $KTOV LifeSci
Post# of 273254
Posted On: 09/25/2016 9:05:54 AM
Kitov Pharamceut Ads (KTOV) 3.25 $KTOV
LifeSci Capital Initiates Coverage of Kitov Pharmaceuticals
ACCESSWIRE - Wed Sep 21, 1:42PM CDT
Developing therapies for simultaneous treatment of osteoarthritis pain and hypertension; Report Available here: http://www.lifescicapital.com/equity-research/kitov/
KTOV: 3.25 (+0.03)
Kitov Pharmaceuticals to Present Data From a U.S. Market Assessment for KIT-302
PR Newswire - Tue Sep 06, 7:16AM CDT
Kitov Pharmaceuticals Holdings Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late stage drug development, will present data from a U.S. Market Assessment of its patented lead drug candidate KIT-302 at the 18th Annual Rodman & Renshaw Global Investment Conference. The conference is being held during September 11-13, 2016, at the Lotte New York Palace Hotel in New York City.
KTOV: 3.25 (+0.03)
Kitov Pharmaceuticals Issues First Half 2016 Financial Reports
PR Newswire - Wed Aug 17, 7:59AM CDT
Kitov Pharmaceuticals Holdings Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late stage drug development, today issued its financial reports for the first half of 2016, ending June 30, 2016.
KTOV: 3.25 (+0.03)
Kitov Announces Issuance of U.S. Patent Securing Long-Term Exclusivity for KIT-302 Ahead of New Drug Application to the FDA
PR Newswire - Wed Aug 10, 12:00AM CDT
Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced that the United States Patent and Trademark Office (USPTO) issued patent # 9,408,837 covering Kitov's lead drug candidate KIT-302 which the Company expects to submit for a New Drug Application to the U.S. Food and Drug Administration by the end of 2016.
KTOV: 3.25 (+0.03)
Kitov Reports New Data Demonstrating KIT-302 Has Beneficial Effects on Kidney Function
PR Newswire - Fri Jun 24, 9:09AM CDT
Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced newly available data from its successfully completed Phase III study of KIT-302 suggest beneficial effects on kidney(renal) function. Damage to renal function is a serious side effect of NSAIDs.
KTOV: 3.25 (+0.03)
Kitov Announces Completion of Manufacturing Pivotal Batches of KIT-302 Required for Registration in the U.S.
PR Newswire - Fri May 27, 6:00AM CDT
Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced the completion of manufacturing by Dexcel Pharma of pivotal batches required for registration of KIT-302 with the U.S. Food and Drug Administration (FDA). This follows Kitov's announcement in December 2015, that KIT-302's pivotal Phase III trial successfully met its primary efficacy endpoint.
KTOV: 3.25 (+0.03)
Kitov Granted Notice of Allowance from U.S. Patent Office for KIT-302
PR Newswire - Thu May 12, 8:18AM CDT
Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, announced today the U.S. Patent and Trademark Office has issued a Notice of Allowance to the Company for claims covering important treatment methodologies, which form the basis of its lead drug candidate, KIT-302, and that ameliorate celecoxib-induced elevation of blood pressure, which can result from prolonged use of the drug.
KTOV: 3.25 (+0.03)
Kitov Reports KIT-302 Study Successfully Meets U.S. Food & Drug Administration Bioequivalence Standards
PR Newswire - Tue May 10, 7:00AM CDT
Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced that KIT-302 has successfully completed its pharmacokinetic (PK) bioequivalence (BE) study and successfully met the U.S. Food and Drug Administration's (FDA) standards for establishing bioequivalence to the reference drugs.
KTOV: 3.25 (+0.03)
Kitov Pharmaceuticals to Present at Pioneers 2016, Presented by Joseph Gunnar, in NYC on May 5, 2016
GlobeNewswire - Wed May 04, 8:25AM CDT
Kitov Pharmaceuticals (NASDAQ:KTOV) (TASE:KTOV), a late-stage drug development company, today announced that Dr. J. Paul Waymack, Kitov's Chairman of the Board and Chief Medical Officer will present at the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar & Co. LLC, taking place on May 5, 2016 in New York.
KTOV: 3.25 (+0.03)
Kitov Creates Pill for Safely Treating Osteoarthritis Pain and Hypertension
ACCESSWIRE - Tue May 03, 9:50AM CDT
NEW YORK, NY / ACCESSWIRE / May 3, 2016 / Combining two existing generic drugs, a new, safer solution to osteoarthritis pain is found; Kitov's drug passed Phase III with stunning results;
JNJ: 118.81 (-0.65), PFE: 34.26 (+0.11), LLY: 81.16 (-0.13), KTOV: 3.25 (+0.03), OA: 74.44 (-0.33)
Kitov Pharmaceuticals to Present at Biotech Showcase in San Francisco on January 11, 2016
PR Newswire - Mon Jan 11, 7:10AM CST
Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), a late-stage drug development company, today announced that Dr. J. Paul Waymack, Kitov's Chairman of the Board and Chief Medical Officer will present at the 8th Annual Biotech Showcase in San Francisco at 5:00pm (Pacific Standard Time) on January 11, 2016. The conference will take place from January 11-13 at the Parc 55 San Francisco. Registered attendees interested in a one-on-one meeting with management may contact the conference or Kitov directly.
KTOV: 3.25 (+0.03)
Kitov Pharmaceuticals Appoints Dr. Gil Ben-Menachem as V.P. of Business Development
PR Newswire - Fri Jan 08, 8:30AM CST
Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), a late-stage drug development company, today announced that it has appointed Dr. Gil Ben-Menachem as Vice President Business Development. The appointment comes following Kitov's recent announcement that the pivotal Phase III trial of its lead drug candidate KIT-302 successfully met its primary endpoint. A combination drug, KIT-302, simultaneously treats osteoarthritis pain as well as hypertension, which is a common side effect of non-steroidal anti-inflammatory (NSAID) drugs.
TEVA: 51.47 (+0.24), KTOV: 3.25 (+0.03)
Kitov Pharmaceuticals Reports Additional Data from its Phase III Trial on the Beneficial Blood Pressure Effects of KIT-302
PR Newswire - Thu Dec 17, 11:30AM CST
Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced more data from its successfully concluded Phase III trial for its lead drug candidate, KIT-302. Data showed the favorable blood pressure effects of KIT-302 were present in all blood pressure variables measured in the study. These data not only confirm the top line findings of the study, they further reveal the benefits of using of a combination drug to improve patient safety when using pain medications.
KTOV: 3.25 (+0.03)
Kitov Pharmaceuticals' Pivotal Phase III Trial Successfully Meets Primary Efficacy Endpoint
PR Newswire - Tue Dec 15, 6:00AM CST
Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, announced today that the Phase III, double-blind, placebo-controlled clinical trial for its leading drug candidate, KIT-302, successfully met the primary efficacy endpoint of the trial protocol as approved by the U.S. Food & Drug Administration (FDA). Data from the trial further revealed that KIT-302 was more efficacious at reducing hypertension than the widely used hypertension drug amlodipine besylate. Kitov plans to file its New Drug Application (NDA) for marketing approval of KIT-302 with the FDA in the second half of 2016. To view a webcast of the press conference discussing these results in Tel Aviv today, please visit: http//bit.ly/1Qi4WfU
KTOV: 3.25 (+0.03)
4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - Thu Dec 10, 12:10PM CST
NEW YORK, NY / ACCESSWIRE / December 10, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at http://www.momentumstockalert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
LOJN: 6.44 (-0.01), XGTI: 0.29 (-0.01), KTOV: 3.25 (+0.03), WAVX: 0.07 (-0.01)
Kitov Pharmaceuticals to Announce Interim Results of the Pivotal Phase III Trial on December 15, 2015 at 7:00am ET
PR Newswire - Thu Dec 10, 7:30AM CST
Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV) (TASE: KTOV), a biopharmaceutical company focused on the development of therapeutic candidates for the simultaneous treatment of various clinical conditions, today announced it expects to have received the completed statistical analysis, and to publish the interim results from its recently concluded pivotal Phase III trial of its combination drug candidate KIT-302 at 7:00am ET on Tuesday, December 15, 2015. In conjunction with the release of the anticipated announcement, Kitov management will hold a press conference at 2:00pm local time in Tel Aviv, Israel at the Hilton Tel Aviv Hotel. The press conference will be webcast live and a playback will be available at www.kitovpharma.com. The link for the live webcast together with an updated company presentation will be published together with interim results.
KTOV: 3.25 (+0.03)
Kitov Pharmaceuticals Holdings Announces Closing of U.S. Initial Public Offering
PR Newswire - Wed Nov 25, 11:10AM CST
Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV) (TASE: KTOV), a biopharmaceutical company focused on the development of therapeutic candidates for the simultaneous treatment of various clinical conditions, today announced the closing of its previously announced underwritten public offering of 3,158,900 American Depository Shares (ADSs), each representing 20 ordinary shares of the Company, and warrants to purchase up to 3,158,900 ADSs. The ADSs and warrants were issued in a fixed combination of one ADS and one warrant to purchase one ADS for a combined price to the public of $4.13. In addition, the underwriters partially exercised their option to purchase an additional 220,074 warrants to purchase 220,074 ADSs. The warrants have a per ADS exercise price of $4.13, are exercisable immediately, and will have a term of five years. In connection with the offering, Kitov has granted the underwriters a 45-day option to purchase up to an additional 473,835 ADSs and/or warrants to purchase an additional 253,761 ADSs (473,835 ADSs before partial exercise announced today) to cover over-allotments, if any, at the public offering price of $4.12 per ADS and $.01 per warrant. The gross proceeds to Kitov from this offering were approximately $13 million, prior to deducting underwriting discounts, commissions and other estimated offering expenses.
KTOV: 3.25 (+0.03)
Kitov Pharmaceuticals Holdings Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing
PR Newswire - Fri Nov 20, 2:17PM CST
Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV), a biopharmaceutical company focused on the development of therapeutic candidates for the simultaneous treatment of various clinical conditions, today announced the pricing of its initial public offering in the United States of 3,158,900 American Depository Shares ("ADSs"
and warrants to purchase up to 3,158,900 ADSs. Each ADS, representing 20 ordinary shares of the Company, and each warrant to purchase one ADS, are offered at a combined price to the public of $4.13. The warrants will have a per ADS exercise price of $4.13, are exercisable immediately, and will have a term of five years.
KTOV: 3.25 (+0.03)
VBL Therapeutics Announces Ron Cohen and Philip Serlin Nominated to Board of Directors
GlobeNewswire - Tue Jan 20, 7:12AM CST
VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory disease, today announced the nomination of industry veterans Ron Cohen, M.D., and Philip Serlin, C.P.A. to stand for election to the Board of Directors at VBL's extraordinary general meeting of shareholders, scheduled for February 11, 2015. Both individuals currently are leaders of biotechnology companies publicly traded in the US: Dr. Cohen serves as the President and Chief Executive Officer of Acorda Therapeutics, Inc. (Nasdaq:ACOR) and Mr. Serlin is Chief Financial and Operating Officer of BioLineRx Ltd. (Nasdaq:BLRX).
KTOV: 3.25 (+0.03), ACOR: 27.28 (+0.06), VBLT: 4.85 (-0.01), DYAX: 38.04 (-0.37), BLRX: 1.28 (+0.27)
LifeSci Capital Initiates Coverage of Kitov Pharmaceuticals
ACCESSWIRE - Wed Sep 21, 1:42PM CDT
Developing therapies for simultaneous treatment of osteoarthritis pain and hypertension; Report Available here: http://www.lifescicapital.com/equity-research/kitov/
KTOV: 3.25 (+0.03)
Kitov Pharmaceuticals to Present Data From a U.S. Market Assessment for KIT-302
PR Newswire - Tue Sep 06, 7:16AM CDT
Kitov Pharmaceuticals Holdings Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late stage drug development, will present data from a U.S. Market Assessment of its patented lead drug candidate KIT-302 at the 18th Annual Rodman & Renshaw Global Investment Conference. The conference is being held during September 11-13, 2016, at the Lotte New York Palace Hotel in New York City.
KTOV: 3.25 (+0.03)
Kitov Pharmaceuticals Issues First Half 2016 Financial Reports
PR Newswire - Wed Aug 17, 7:59AM CDT
Kitov Pharmaceuticals Holdings Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late stage drug development, today issued its financial reports for the first half of 2016, ending June 30, 2016.
KTOV: 3.25 (+0.03)
Kitov Announces Issuance of U.S. Patent Securing Long-Term Exclusivity for KIT-302 Ahead of New Drug Application to the FDA
PR Newswire - Wed Aug 10, 12:00AM CDT
Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced that the United States Patent and Trademark Office (USPTO) issued patent # 9,408,837 covering Kitov's lead drug candidate KIT-302 which the Company expects to submit for a New Drug Application to the U.S. Food and Drug Administration by the end of 2016.
KTOV: 3.25 (+0.03)
Kitov Reports New Data Demonstrating KIT-302 Has Beneficial Effects on Kidney Function
PR Newswire - Fri Jun 24, 9:09AM CDT
Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced newly available data from its successfully completed Phase III study of KIT-302 suggest beneficial effects on kidney(renal) function. Damage to renal function is a serious side effect of NSAIDs.
KTOV: 3.25 (+0.03)
Kitov Announces Completion of Manufacturing Pivotal Batches of KIT-302 Required for Registration in the U.S.
PR Newswire - Fri May 27, 6:00AM CDT
Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced the completion of manufacturing by Dexcel Pharma of pivotal batches required for registration of KIT-302 with the U.S. Food and Drug Administration (FDA). This follows Kitov's announcement in December 2015, that KIT-302's pivotal Phase III trial successfully met its primary efficacy endpoint.
KTOV: 3.25 (+0.03)
Kitov Granted Notice of Allowance from U.S. Patent Office for KIT-302
PR Newswire - Thu May 12, 8:18AM CDT
Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, announced today the U.S. Patent and Trademark Office has issued a Notice of Allowance to the Company for claims covering important treatment methodologies, which form the basis of its lead drug candidate, KIT-302, and that ameliorate celecoxib-induced elevation of blood pressure, which can result from prolonged use of the drug.
KTOV: 3.25 (+0.03)
Kitov Reports KIT-302 Study Successfully Meets U.S. Food & Drug Administration Bioequivalence Standards
PR Newswire - Tue May 10, 7:00AM CDT
Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced that KIT-302 has successfully completed its pharmacokinetic (PK) bioequivalence (BE) study and successfully met the U.S. Food and Drug Administration's (FDA) standards for establishing bioequivalence to the reference drugs.
KTOV: 3.25 (+0.03)
Kitov Pharmaceuticals to Present at Pioneers 2016, Presented by Joseph Gunnar, in NYC on May 5, 2016
GlobeNewswire - Wed May 04, 8:25AM CDT
Kitov Pharmaceuticals (NASDAQ:KTOV) (TASE:KTOV), a late-stage drug development company, today announced that Dr. J. Paul Waymack, Kitov's Chairman of the Board and Chief Medical Officer will present at the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar & Co. LLC, taking place on May 5, 2016 in New York.
KTOV: 3.25 (+0.03)
Kitov Creates Pill for Safely Treating Osteoarthritis Pain and Hypertension
ACCESSWIRE - Tue May 03, 9:50AM CDT
NEW YORK, NY / ACCESSWIRE / May 3, 2016 / Combining two existing generic drugs, a new, safer solution to osteoarthritis pain is found; Kitov's drug passed Phase III with stunning results;
JNJ: 118.81 (-0.65), PFE: 34.26 (+0.11), LLY: 81.16 (-0.13), KTOV: 3.25 (+0.03), OA: 74.44 (-0.33)
Kitov Pharmaceuticals to Present at Biotech Showcase in San Francisco on January 11, 2016
PR Newswire - Mon Jan 11, 7:10AM CST
Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), a late-stage drug development company, today announced that Dr. J. Paul Waymack, Kitov's Chairman of the Board and Chief Medical Officer will present at the 8th Annual Biotech Showcase in San Francisco at 5:00pm (Pacific Standard Time) on January 11, 2016. The conference will take place from January 11-13 at the Parc 55 San Francisco. Registered attendees interested in a one-on-one meeting with management may contact the conference or Kitov directly.
KTOV: 3.25 (+0.03)
Kitov Pharmaceuticals Appoints Dr. Gil Ben-Menachem as V.P. of Business Development
PR Newswire - Fri Jan 08, 8:30AM CST
Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), a late-stage drug development company, today announced that it has appointed Dr. Gil Ben-Menachem as Vice President Business Development. The appointment comes following Kitov's recent announcement that the pivotal Phase III trial of its lead drug candidate KIT-302 successfully met its primary endpoint. A combination drug, KIT-302, simultaneously treats osteoarthritis pain as well as hypertension, which is a common side effect of non-steroidal anti-inflammatory (NSAID) drugs.
TEVA: 51.47 (+0.24), KTOV: 3.25 (+0.03)
Kitov Pharmaceuticals Reports Additional Data from its Phase III Trial on the Beneficial Blood Pressure Effects of KIT-302
PR Newswire - Thu Dec 17, 11:30AM CST
Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced more data from its successfully concluded Phase III trial for its lead drug candidate, KIT-302. Data showed the favorable blood pressure effects of KIT-302 were present in all blood pressure variables measured in the study. These data not only confirm the top line findings of the study, they further reveal the benefits of using of a combination drug to improve patient safety when using pain medications.
KTOV: 3.25 (+0.03)
Kitov Pharmaceuticals' Pivotal Phase III Trial Successfully Meets Primary Efficacy Endpoint
PR Newswire - Tue Dec 15, 6:00AM CST
Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, announced today that the Phase III, double-blind, placebo-controlled clinical trial for its leading drug candidate, KIT-302, successfully met the primary efficacy endpoint of the trial protocol as approved by the U.S. Food & Drug Administration (FDA). Data from the trial further revealed that KIT-302 was more efficacious at reducing hypertension than the widely used hypertension drug amlodipine besylate. Kitov plans to file its New Drug Application (NDA) for marketing approval of KIT-302 with the FDA in the second half of 2016. To view a webcast of the press conference discussing these results in Tel Aviv today, please visit: http//bit.ly/1Qi4WfU
KTOV: 3.25 (+0.03)
4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - Thu Dec 10, 12:10PM CST
NEW YORK, NY / ACCESSWIRE / December 10, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at http://www.momentumstockalert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
LOJN: 6.44 (-0.01), XGTI: 0.29 (-0.01), KTOV: 3.25 (+0.03), WAVX: 0.07 (-0.01)
Kitov Pharmaceuticals to Announce Interim Results of the Pivotal Phase III Trial on December 15, 2015 at 7:00am ET
PR Newswire - Thu Dec 10, 7:30AM CST
Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV) (TASE: KTOV), a biopharmaceutical company focused on the development of therapeutic candidates for the simultaneous treatment of various clinical conditions, today announced it expects to have received the completed statistical analysis, and to publish the interim results from its recently concluded pivotal Phase III trial of its combination drug candidate KIT-302 at 7:00am ET on Tuesday, December 15, 2015. In conjunction with the release of the anticipated announcement, Kitov management will hold a press conference at 2:00pm local time in Tel Aviv, Israel at the Hilton Tel Aviv Hotel. The press conference will be webcast live and a playback will be available at www.kitovpharma.com. The link for the live webcast together with an updated company presentation will be published together with interim results.
KTOV: 3.25 (+0.03)
Kitov Pharmaceuticals Holdings Announces Closing of U.S. Initial Public Offering
PR Newswire - Wed Nov 25, 11:10AM CST
Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV) (TASE: KTOV), a biopharmaceutical company focused on the development of therapeutic candidates for the simultaneous treatment of various clinical conditions, today announced the closing of its previously announced underwritten public offering of 3,158,900 American Depository Shares (ADSs), each representing 20 ordinary shares of the Company, and warrants to purchase up to 3,158,900 ADSs. The ADSs and warrants were issued in a fixed combination of one ADS and one warrant to purchase one ADS for a combined price to the public of $4.13. In addition, the underwriters partially exercised their option to purchase an additional 220,074 warrants to purchase 220,074 ADSs. The warrants have a per ADS exercise price of $4.13, are exercisable immediately, and will have a term of five years. In connection with the offering, Kitov has granted the underwriters a 45-day option to purchase up to an additional 473,835 ADSs and/or warrants to purchase an additional 253,761 ADSs (473,835 ADSs before partial exercise announced today) to cover over-allotments, if any, at the public offering price of $4.12 per ADS and $.01 per warrant. The gross proceeds to Kitov from this offering were approximately $13 million, prior to deducting underwriting discounts, commissions and other estimated offering expenses.
KTOV: 3.25 (+0.03)
Kitov Pharmaceuticals Holdings Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing
PR Newswire - Fri Nov 20, 2:17PM CST
Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV), a biopharmaceutical company focused on the development of therapeutic candidates for the simultaneous treatment of various clinical conditions, today announced the pricing of its initial public offering in the United States of 3,158,900 American Depository Shares ("ADSs"
and warrants to purchase up to 3,158,900 ADSs. Each ADS, representing 20 ordinary shares of the Company, and each warrant to purchase one ADS, are offered at a combined price to the public of $4.13. The warrants will have a per ADS exercise price of $4.13, are exercisable immediately, and will have a term of five years. KTOV: 3.25 (+0.03)
VBL Therapeutics Announces Ron Cohen and Philip Serlin Nominated to Board of Directors
GlobeNewswire - Tue Jan 20, 7:12AM CST
VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory disease, today announced the nomination of industry veterans Ron Cohen, M.D., and Philip Serlin, C.P.A. to stand for election to the Board of Directors at VBL's extraordinary general meeting of shareholders, scheduled for February 11, 2015. Both individuals currently are leaders of biotechnology companies publicly traded in the US: Dr. Cohen serves as the President and Chief Executive Officer of Acorda Therapeutics, Inc. (Nasdaq:ACOR) and Mr. Serlin is Chief Financial and Operating Officer of BioLineRx Ltd. (Nasdaq:BLRX).
KTOV: 3.25 (+0.03), ACOR: 27.28 (+0.06), VBLT: 4.85 (-0.01), DYAX: 38.04 (-0.37), BLRX: 1.28 (+0.27)
(0)
(0)Scroll down for more posts ▼